TYK Medicines Wins China Approval for Asandeutertinib in EGFR-Mutant NSCLC With Brain Metastases
China’s NMPA has granted conditional approval to asandeutertinib (TY-9591), TYK Medicines’ brain-penetrant, deuterated EGFR inhibitor, for the first-line treatment of patients with EGFR-mutated non-small cell lung cancer with central nervous…
CSPC’s EGFR ADC SYS6010 Beats Chemotherapy in Phase 3 NSCLC Trial, Setting Stage for Potential Regulatory Filing
CSPC Pharmaceutical Group’s experimental EGFR-targeting antibody-drug conjugate SYS6010 has met the primary endpoint in the pivotal Phase III SYNSTAR-01 trial, significantly improving progression-free survival over platinum-based chemotherapy in…
AusperBio Raises $120 Million Series C to Advance AHB-137 Toward Hepatitis B Functional Cure and Commercialization
AusperBio has raised $120 million in Series C financing to advance its lead chronic hepatitis B therapy AHB-137 through Phase III development and prepare for potential commercialization, while expanding a next-generation pipeline of siRNA and combination…
DualityBio Partners with Genentech in $1B-Plus Next-Generation ADC Collaboration Built Around Novel Payload Platform
China’s Duality Biotherapeutics has signed a global research, development and licensing agreement with Roche’s Genentech to develop a new generation of antibody-drug conjugates designed to overcome resistance to payloads used in today’s…
Biokin Pharmaceutical
Building a Global Oncology Franchise Around Bispecific ADCs
Haisco Pharmaceutical Group
From Chinese Specialty Pharma to Global Innovative Drug Developer
Akeso, Inc.
Building a Global Bispecific Antibody and Next-Generation Oncology Franchise
BioShanghai Week 2026
BioShanghai Week 2026 (or Shanghai International Biopharma Industry Week) will be held September 17–20, 2026 at Zhangjiang Science Hall, Shanghai. Since its sixth edition, BioShanghai Week has become a iconic platform for biopharmaceutical innovation and…
CPHI & PMEC Shenzhen 2026
China is the world’s 2nd largest pharma market, which is valued at USD 282.07bn in 2024, and projected to reach USD 402bn by 2029. AI in pharma is surging at 41.52% CAGR, the fastest across all sectors. Why Shenzhen? Shenzhen’s 1,300+ biotech…
Clinical Trial Supply China 2026
Clinical Trial Supply China is returning for a second year! This is your gateway to understanding and excelling in the rapidly evolving landscape of clinical trial logistics in China. Why attend? Navigate Local Challenges: Gain critical insights into the…